Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GASPAR: Genistein in Heart Failure and TTR Amyloidosis
NCT06634108Phase 2Recruiting
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of genistein in heart failure with reduced ejection fraction (HFrEF) and transthyretin amyloid cardiomyopathy (ATTR-CM). Primary endpoints: Change in Inflammatory Markers at 18 weeks, Change in Cardiac Biomarkers at 18 weeks and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
genistein
03
Conditions
heart failure with reduced ejection fraction (HFrEF)transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT06634108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06634108.